However, combination therapy, such as co-inhibition of anti-PD-1 and STAT3 or regorafenib, a small molecule tyrosine kinase inhibitor, can elicit an effective antitumor response in a small subset of MSS CRC patients (49, 94). The gene discussed is PDCD1; the disease is colorectal carcinoma.